STK11 and non-small cell lung carcinoma: Although it is currently recommended that patients with STK11 or KEAP mutation-positive NSCLC should receive standard-of-care CIT (8–10), the introduction of IO has not improved the outlook for these patients (22, 51), who continue to have relatively poor outcomes, irrespective of the treatment regimen given (Table 1B).